Enanta Pharmaceuticals (ENTA) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

14

Hold

3

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.96

Median Target+54.32%

$20.00

Potential upside vs current price

Current Stock Price

$12.96

Median Target+54.32%

$20.00

Potential upside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

14

Hold

3

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.96

Median Target+54.32%

$20.00

Potential upside vs current price

Current Stock Price

$12.96

Median Target+54.32%

$20.00

Potential upside vs current price

Enanta Pharmaceuticals, Inc.